MedTrace Logo

Neoadjuvant Chemotherapy for Patients With Advanced Gastric Cancer in ERAS Programs for Radical Gastrectomy

NCT03238404 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2017-08-03

No results posted yet for this study

Summary

Patients with advanced gastric cancer received neoadjuvant chemotherapy undergo enhanced recovery after surgery (ERAS) programs.

Conditions

Interventions

PROCEDURE

NAC group

NAC is the name of a procedure. NAC doesn't mean different interventions are used. Patients in this group need receive this NAC procedure instead of one drug before the gastrectomy and ERAS. The program consists of an intravenous injection of 130 mg/m2 oxaliplatin on day 1, followed by oral administration of 50 mg tegafur gimerac (the name of an anticarcinogen) twice daily on days 1-14, every 3 weeks.

PROCEDURE

Surgery alone group

Patients will not receive neoadjuvant chemotherapy and they will undergo the gastrectomy and ERAS alone.

Sponsors & Collaborators

  • JIANG Zhi-Wei

    lead OTHER

Principal Investigators

  • Zhi-Wei JIANG, Ph.D. · Jinling Hospital, Medical School of Nanjing University

  • Jian ZHAO, Ph.D. · Jinling Hospital, Medical School of Nanjing University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-01
Primary Completion
2016-08-10
Completion
2016-12-20

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03238404 on ClinicalTrials.gov